In a multicenter randomized trial in patients with active Graves' ophthalmopathy<unk>  was more effective than placebo. In February 2019, Horizon announced results from a Phase III confirmatory trial evaluating<unk>  for the treatment of active thyroid eye disease (TED). The study met its primary endpoint, showing more patients treated with<unk>  compared with placebo had a meaningful improvement in proptosis, or bulging of the eye: 82.9 percent of<unk>  patients compared to 9.5 percent of placebo patients achieved the primary endpoint of a 2 mm or more reduction in proptosis (p<0.001). Proptosis is the main cause of morbidity in TED. All secondary endpoints were also met and the safety profile was consistent with the Phase II study of<unk>  in TED. On 10 July 2019, Horizon submitted a Biologics License Application (BLA) to the FDA for<unk>  for the treatment of active thyroid eye disease (TED). Horizon requested priority review for the application - if so granted (FDA has a 60-day review period to decide) it would result in a max. 6 month review process.
Teprotumumab
Bezlotoxumab
Sacituzumab govitecan
Tisotumab vedotin
Alirocumab
Tralokinumab
Evolocumab
Anifrolumab